Cost-effectiveness Analysis of 2 Kinds of Moderate Intensity Statins Plan in the Treatment of Hyperlipid-emia
10.6039/j.issn.1001-0408.2017.26.03
- VernacularTitle:两种中等强度他汀类药物方案治疗高脂血症的成本-效果分析
- Author:
Shenghong GUO
;
Yan'an WANG
;
Wenwu SUN
;
Shuping WAN
;
Zhihua SUN
;
Guanglong YANG
;
Lihua ZHU
;
- Keywords:
Atorvastatin;
Rosuvastatin;
Hyperlipoidemia;
Cost-effectiveness analysis;
Pharmacoeconomics;
Moderate intensi-ty statins plan
- From:
China Pharmacy
2017;28(26):3610-3613
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effectiveness and economics of 10 mg/d rosuvastatin and 20 mg/d atorvastatin in the treatment of hyperlipidemia (HLP). METHODS:The information of 180 HLP patients selected from Tianmen Municipal First People's Hospital during Mar. 2015-Feb. 2016 were divided into group A and B according to medication regimen,with 90 cases in each group. Group A was given Atorvastatin calcium tablet 20 mg,qd;group B was given Rosuvastatin calcium tablet 10 mg,qd. Treatment course of 2 groups lasted for 8 weeks. Blood lipid indexes before and after treatment,lipid-lowering efficacy,the rate of qualified blood lipid and the occurrence of ADR after treatment were compared between 2 groups. Cost-effectiveness analysis was adopted for economic evaluation. RESULTS:Before treatment,there was no statistical significance in the levels of blood lipid in-dexes between 2 groups (P>0.05). After treatment,TC and LDL-C levels of 2 groups were significantly lower than before treat-ment,and those of group B were significantly lower than those of group A,with statistical significance(P<0.05). Total response rate of lipid-lowering in group B(97.78％)was significantly higher than group A(86.67％),and the rate of qualified blood lipid (66.67％)was also significantly higher than group A(51.11％),with statistical significance(P<0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). The costs of group A and B were 488.32,436.24 yuan,and cost-effectiveness ratios were 5.63,4.46;incremental cost-effectiveness ratio was -4.69. The plan of group B had cost-effective-ness advantage. The results of cost-effectiveness analysis were supported by sensitivity analysis. CONCLUSIONS:In the view of short-term efficacy,10 mg/d rosuvastatin plan is better than 20 mg/d atorvastatin plan in lowering lipid and has cost-effectiveness advantage,and both have similar safety.
